States

FDA Haryana booked Blood Centre for selling Plasma more than the price fixed, FIR lodged

Hence to sale a blood component in violation above rate prescribed by competent authority is also a matter of cheating and dishonesty and this case is clear cut case of profiteering.

The Health Master

May 21, 2022

1458

Blood Bank Centre Donation Unit — Picture: Pixabay

Last Updated on January 14, 2024 by The Health Master

Food and Drugs Administration (FDA) Haryana raided Blood Centre and caught them red handed selling plasma Plasma more than the price fixed. FIR has also been lodged against the Blood Centre and the purchasers of the plasma.

FDA Haryana

On 21-05-2022 the team comprising of Sarika Malik, Senior Drugs Control officer, Kurukshetra Zone, Kurukshetra, Amandeep Singh Chauhan, Drugs Control officer Nuh, Gurugram Zone, Sandeep Kumar, Drugs Inspector, CDSCO, NZ Ghaziabad Under supervision of Ripan Mehta, Asst. State Drugs Controller, FDA Haryana visited Shah Krishan Sewa Blood Centre, Near Koel Complex, Kaithal, Haryana

The blood centre found indulged in business of profiteering through the way of selling Fresh Frozen Plasma BP to Virchow Biotech Private Limited and Intas Pharmaceuticals Limited for Rs. 2800/- and Rs. 2700/- per litre violating the Plasma Policy of, Haryana State Blood Transfusion Council, where the price of Plasma had been fixed Rs. 1600/- per litre.

Click for more articles on FDA Haryana

Blood Products and Plasma substitutes is in National List of Essential Medicine issued by National Pharmaceutical Pricing Agency (NPPA) an agency who fixes the MRP of the Medicines. In the present case NPPA is not the fixing agency for Plasma and the State Blood Transfusion Council are price fixing agency for Plasma.

The MoU of Intas Pharmaceuticals Limited mentions rate of FFP as Rs. 2700/- however the component FFP sold for Rs. 2900/-, further in the agreement with Virchow Biotech Private Limited there was no rate specified in the agreement, however the component FFP was sold for Rs. 2800/- per litre.

None of the MoU of Virchow Biotech Private Limited and Intas Pharmaceuticals Limited with the blood center was sent to the State Drugs Controller for approval before supplying excess plasma to indigenous fractionators violating the Plasma Policy.

Hence to sale a blood component in violation above rate prescribed by competent authority is also a matter of cheating and dishonesty and this case is clear cut case of profiteering.

Further, selling component i.e. Fresh Frozen Plasma BP at higher prices which is essentially required by masses and fractionators to prevent the deadly disease the person named above have done a serious offence under Drugs Price Control Order 2013 (DPCO) and order under Section 3 of Essential Commodities 1955 Act punishable under Section 7 of the EC Act in violation of selling above prescribed rates.

FDA Haryana lodged a FIR against representatives / responsible persons of Shah Krishan Sewa Blood Centre, Virchow Biotech Private Limited and Intas Pharmaceuticals Limited and all other person responsible for violation of law of land i.e. Indian Penal Code and Drugs Price Control Order 2013 and Essential Commodities Act 1955 for overcharging and also for the act of cheating and dishonesty of all for financial gains by selling the blood components i.e. Fresh Frozen Plasma BP.

Also read

Latest on National Pharmaceutical Pricing Authority (NPPA)

Latest notifications – DPCO / NPPA

Latest Notifications: EC Act (Essential Commodities Act)

FAQs – On DPCO: Drugs (Prices Control) Order, 2013

Must read

Procedure to obtain license for Blood Centre (Blood Bank)

Latest Notifications: Blood Centre / Bank

Blood Centre (Bank) – requirements at a glance

FAQs – on Blood Bank / Centre (Part-1)

FAQs – on Blood Bank / Centre (Part-2)

FAQs – on Blood Bank / Centre (Part-3)